

Press
release

Montpellier, France, June 22, 2021 – 5:45pm CEST

Intrasense: successful Rights Issue with €4.9 million raised

Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions and Myrian® designer (the “**Company**”), today announced the success of its capital increase through the issuance of new shares (“**New Shares**”) with shareholders’ preferential subscription rights, for which subscriptions took place between May 28 and June 15, 2021 (the “**Rights Issue**”).

The gross amount of the Rights Issue was €4.9 million and resulted in the issuance of 6,961,647 New Shares, subscribed at a price of €0.70 per New Share, representing a 22.65% face discount compared to the last quoted price before suspension of the listing on May 24, 2021, i.e. €0.905.

The proceeds from this issuance of New Shares are intended to finance the following areas of expenditure:

- Innovation: recruitment of talent to strengthen the R&D team;
- Marketing: development of strategic partners and key opinion leaders’ networks;
- Sales: strengthen of sales teams and product launch in Germany.

Thus, it is expected that approximately 60% of the proceeds will be allocated to R&D for the development of a new oncology product line as well as for the evolution of the current Myrian product line. Approximately 40% of the proceeds will be allocated to the marketing and commercial development of the Company in Europe and China.

Nicolas Reymond, CEO of Intrasense, stated: “*On behalf of the Board of Directors and all our team, I would like to thank all of the investors who contributed to the success of this capital increase. The great deal of interest expressed for this rights issue demonstrates the appeal of our growth strategy based on the development of two product lines with high levels of technological synergies and their marketing in the promising area of oncology software solutions incorporating artificial intelligence. Intrasense now has the financial resources necessary to realize* its

Do not distribute or disseminate, directly or indirectly, in the United States, Canada, Australia or Japan. This press release does not constitute an offer of securities or an invitation to buy, subscribe or sell securities in the United States or in any other jurisdiction in which it would be illegal to do so.

ambitions of achieving €30 million in revenue within five years' time and becoming a world leader in oncology-focused medical imaging."

Results of the Rights Issue

At the end of the subscription period, subscriptions totaled 11,290,510 shares, divided as follows:

- 3,499,418 New Shares were subscribed on an irreducible basis;
- 7,791,092 New Shares were requested on a reducible basis, corresponding to a subscription rate of approximately 1.6 times the target amount of the capital increase (including the commitments received prior to the launch of the operation).

The Rights Issue amounted at €4,873,153 and resulted in the issuance of 6,961,647 New Shares, subscribed at a price of €0.70 per New Share, divided as follows:

- 3,499,418 New Shares were subscribed on an irreducible basis;
- 3,462,229 New Shares were subscribed on a reducible basis.

The Company's share capital following the Rights Issue amounts to €1,566,370.70 divided into 31,327,414 shares with par value of €0.05 each.

Settlement-delivery of the New Shares and their admission to trading on Euronext Growth Paris are scheduled to take place on June 24 and June 25, 2021 respectively.

The New Shares will rank for dividends immediately and will be traded on the same listing line as the existing shares (ISIN FR0011179886).

Indicative timetable for the operation:

June 24, 2021	- Issue of the New Shares - Settlement-delivery of the New Shares
June 25, 2021	- Admission of the New Shares to trading on Euronext Growth Paris

Do not distribute or disseminate, directly or indirectly, in the United States, Canada, Australia or Japan. This press release does not constitute an offer of securities or an invitation to buy, subscribe or sell securities in the United States or in any other jurisdiction in which it would be illegal to do so.



Impact on a shareholder's position

The effect of the issue on the stake of a shareholder who holds 1% of the Company's share capital but chooses not to subscribe shares in the Rights Issue (based on the number of shares comprising the Company's share capital on May 24, 2021) is as follows:

	Share capital (%)	
	Non-diluted basis	Diluted basis*
Before issue	1.00	0.88
After the issue of 6,961,647 New Shares	0.78	0.70

* in the event of the exercise of instruments giving access to the capital representing a maximum number of 3,410,086 potential New Shares.

Impact on equity

The impact of the issue on consolidated equity per share (based on the Company's consolidated equity at December 31, 2020 and the number of shares making up the Company's share capital on December 31, 2020) is as follows:

	Equity per share (€)	
	Non-diluted basis	Diluted basis*
Before issue	0.088	0.078
After the issue of 6,961,647 New Shares	0.069	0.062

* in the event of the exercise of instruments giving access to the capital representing a maximum number of 3,410,086 potential New Shares.

Do not distribute or disseminate, directly or indirectly, in the United States, Canada, Australia or Japan. This press release does not constitute an offer of securities or an invitation to buy, subscribe or sell securities in the United States or in any other jurisdiction in which it would be illegal to do so.




About Intrasense

Founded in 2004, Intrasense develops and markets a unique medical device named Myrian®, a software platform facilitating and ensuring diagnosis, decision-making and therapeutic follow-up. Thanks to Myrian®, more than 1000 hospitals and clinics spread over 40 countries use a unique and integrated platform supporting all types of imaging modalities (MRI, scanner...). Enriched with expert clinical modules dedicated to specific pathologies and organs, Myrian® provides a universal medical image processing solution which can be fully integrated into any healthcare information system. Intrasense has more than 40 employees among which 15 are dedicated to Research & Development. Intrasense has been labelled 'innovative company' by the BPI and has invested more than 10 million euros in Research & Development since its creation. More information on: www.intrasense.fr

Contacts

Intrasense
Jérémy Peyron
Marketing & Communication manager
1231 avenue du Mondial 98, 34000
Montpellier, FRANCE
Tel: +334 67 130 130
investor@intrasense.fr

NewCap
Investor Relations and Financial
Communication
Louis Tilquin
Paris, FRANCE
Tel: +331 44 71 20 40
intrasense@newcap.eu



Do not distribute or disseminate, directly or indirectly, in the United States, Canada, Australia or Japan. This press release does not constitute an offer of securities or an invitation to buy, subscribe or sell securities in the United States or in any other jurisdiction in which it would be illegal to do so.